• PTC Therapeutics was selected as winning bidder to acquire Sangamo’s ST-920 Fabry disease gene therapy in a competitive bankruptcy auction.
• Deal terms include USD 111 million upfront, up to USD 100 million in contingent milestone payments tied to certain regulatory approvals.
• Rolling BLA submission to the FDA for accelerated approval is expected to be completed in Q4 2026; potential commercial launch targeted for 2027.
• Transaction is expected to close in late Q3 or early Q4 2026, subject to definitive documentation, court approval, antitrust review, closing conditions.
• PTC plans to use its existing rare-disease commercial footprint to support US launch, with plans to pursue approvals outside the US.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PTC Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608121601PR_NEWS_USPR_____NY25305) on August 12, 2026, and is solely responsible for the information contained therein.